APTITUDE HEALTH®

EPICS

Global Perspectives in Current and Future Management of Lung Cancer

October 20, 2025

Report Contents

EPICS

Content	Link
Meeting Snapshot	
Faculty Panel	
Meeting Agenda	
Key Insights and Strategic Recommendations	
Can We Improve on Current IO ± Chemo in Metastatic NSCLC?	
Expanding Approaches in Stage IV *EGFR*-Mutated NSCLC	
Targeted Therapy Beyond *EGFR* in Stage IV NSCLC	
Small Cell Lung Cancer and Mesothelioma	
Stage I–III NSCLC: Immunotherapy and Targeted Therapy	

Meeting Snapshot

EPICS

A live, closed-door roundtable discussion focused on lung cancer was held on **October 20, 2025**

Lung cancer-specific discussions on latest research updates, therapeutic advances, and their application in clinical decision-making were led by **Corey Langer, MD, FACP**, from the University of Pennsylvania

The panel consisted of 8 key experts in lung cancer

- 3 from Europe
- 5 from US



Insights report includes postmeeting analyses and actionable recommendations

Panel Consisting of 5 US and 3 European Lung Cancer Experts

EPICS



CHAIR:
Corey Langer, MD, FACP
University of Pennsylvania

Benjamin Besse, MD, PhD
Gustave Roussy and Paris-Saclay University

Roy Herbst, MD, PhD
Yale Cancer Center

Marina Chiara Garassino, MD
University of Chicago

Julie Brahmer, MD
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Solange Peters, MD, PhD
University Hospital of Lausanne

Heather Wakelee, MD
Stanford Cancer Institute

Luis Paz-Ares, MD, PhD
Hospital Universitario 12 de Octubre

APTITUDE HEALTH®

Meeting Agenda

EPICS

Time (CEST)	Topic	Speaker/Moderator
19.30 – 19.35 (5 min)	**Welcome and Introductions**	Corey J. Langer, MD, FACP
19.35 – 19.50 (15 min)	**Can We Improve on Current IO ± Chemo in Metastatic NSCLC?**	Marina Chiara Garassino, MD
19.50 – 20.20 (30 min)	Discussion	All faculty
20.20 – 20.35 (15 min)	**Expanding Approaches in Stage IV *EGFR*-Mutated NSCLC**	Roy Herbst, MD, PhD
20.35 – 21.05 (30 min)	Discussion	All faculty
21.05 – 21.20 (15 min)	**Targeted Therapy Beyond *EGFR* in Stage IV NSCLC**	Julie Brahmer, MD; Solange Peters, MD, PhD
21.20 – 21.50 (30 min)	Discussion	All faculty
21.50 – 22.00 (10 min)	BREAK	
22.00 – 22.15 (15 min)	**Small Cell Lung Cancer and Mesothelioma**	Luis Paz-Ares, MD, PhD; Benjamin Besse, MD, PhD
22.15 – 22.45 (30 min)	Discussion	All faculty
22.45 – 23.00 (15 min)	**Stage I–III NSCLC: Immunotherapy and Targeted Therapy**	Heather Wakelee, MD
23.00 – 23.25 (25 min)	Discussion	All faculty
23.25 – 23.30 (5 min)	**Wrap-Up Comments and Adjourn**	Corey J. Langer, MD, FACP

APTITUDE HEALTH®

EPICS

Can We Improve on Current IO ± Chemo in Metastatic NSCLC?

Conference Highlights Presented by
Marina Chiara Garassino, MD

Abstract Selection

EPICS

Abstract	Phase
Abstract 1851MO: Pembrolizumab plus chemotherapy (PEM + CT) versus pembrolizumab (PEM) as first-line therapy for advanced NSCLC with PD-L1 tumor proportion score (TPS) ≥50%: Open-label, phase 3, randomized trial (PAULIEN) (Houda I, et al)	Phase III
Abstract LBA4: Phase III study of ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small cell lung cancer (HARMONi-6) (Lu S, et al)	Phase III
Abstract LBA71: Final Analysis of First-Line Serplulimab Plus Chemotherapy With or Without HLX04 in Advanced Nonsquamous Non-Small Cell Lung Cancer: The ASTRUM-002 Phase 3 Study (Shi YK, et al)	Phase III
Abstract 1850MO: TeLuRide-005: Phase 2 Study of EIK1001, a Toll-Like Receptor 7/8 (TLR7/8) Co-Agonist With Pembrolizumab (pembro)+Chemotherapy (chemo) as First-Line (1L) Therapy in Stage 4 Non-Small Cell Lung Cancer (NSCLC) (Gralla RJ, et al)	Phase II
Abstract 1853MO: Efficacy and Safety of Rilvegostomig, an Anti-PD-1/TIGIT Bispecific Antibody, for Checkpoint Inhibitor (CPI)-Naïve Metastatic Non-Small Cell Lung Cancer (mNSCLC): ARTEMIDE-01 (Cho BC, et al)	Phase II
Abstract 1852MO: KEYMAKER-U01 Substudy 01A: Investigational Agents + Pembrolizumab (Pembro) and Chemotherapy (Chemo) in Untreated Stage IV Non-Small Cell Lung Cancer (NSCLC) (Aggarwal C, et al)	Phase II
Abstract 1947P: Phase 2 Study of Sacituzumab Govitecan (SG), Domvanalimab (dom), and Zimberelimab (zim) in Metastatic Non-Small Cell Lung Cancer (mNSCLC): VELOCITY-Lung Substudy-01 (Ahn MJ, et al)	Phase II

Pembrolizumab plus chemotherapy (PEM + CT) versus pembrolizumab (PEM) as first-line therapy for advanced NSCLC with PD-L1 tumor proportion score (TPS) ≥50%: Open-label, phase 3, randomized trial (PAULIEN)

EPICS

Houda I, et al. ESMO 2025. Abstract 1851MO

Phase III study of ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line Treatment for advanced squamous non-small cell lung cancer (HARMONi-6)

Lu S, et al. ESMO 2025. Abstract LBA4

EPICS

Phase III study of ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line Treatment for advanced squamous non-small cell lung cancer (HARMONi-6)

Lu S, et al. ESMO 2025. Abstract LBA4

EPICS



APTITUDE HEALTH®

Final Analysis of First-Line Serplulimab Plus Chemotherapy With or Without HLX04 in Advanced Nonsquamous Non-Small Cell Lung Cancer: The ASTRUM-002 Phase 3 Study

Shi YK, et al. ESMO 2025. Abstract LBA71

EPICS

TeLuRide-005: Phase 2 Study of EIK1001, a Toll-Like Receptor 7/8 (TLR7/8) Co-Agonist With Pembrolizumab (pembro)+Chemotherapy (chemo) as First-Line (1L) Therapy in Stage 4 Non-Small Cell Lung Cancer (NSCLC)

Gralla RJ, et al. ESMO 2025. Abstract 1850MO

EPICS

APTITUDE HEALTH®

Efficacy and Safety of Rilvegostomig, an Anti-PD-1/TIGIT Bispecific Antibody, for Checkpoint Inhibitor (CPI)-Naïve Metastatic Non-Small Cell Lung Cancer (mNSCLC): ARTEMIDE-01

Cho BC, et al. ESMO 2025. Abstract 1853MO

EPICS

APTITUDE HEALTH®

Efficacy and Safety of Rilvegostomig, an Anti-PD-1/TIGIT Bispecific Antibody, for Checkpoint Inhibitor (CPI)-Naïve Metastatic Non-Small Cell Lung Cancer (mNSCLC): ARTEMIDE-01

Cho BC, et al. ESMO 2025. Abstract 1853MO

EPICS



APTITUDE HEALTH®

KEYMAKER-U01 Substudy 01A: Investigational Agents + Pembrolizumab (Pembro) and Chemotherapy (Chemo) in Untreated Stage IV Non-Small Cell Lung Cancer (NSCLC)

Aggarwal C, et al. ESMO 2025. Abstract 1852MO

EPICS

Phase 2 Study of Sacituzumab Govitecan (SG), Domvanalimab (dom), and Zimberelimab (zim) in Metastatic Non-Small Cell Lung Cancer (mNSCLC): VELOCITY-Lung Substudy-01

Ahn MJ, et al. ESMO 2025. Abstract 1947P

EPICS

APTITUDE HEALTH®

APTITUDE HEALTH®

EPICS

Can We Improve on Current IO ± Chemo in Metastatic NSCLC?

Discussion

Can We Improve on Current IO ± Chemo in Metastatic NSCLC? (1/4)

EPICS

APTITUDE HEALTH®

Can We Improve on Current IO ± Chemo in Metastatic NSCLC? (2/4)

EPICS

[redacted]

Can We Improve on Current IO ± Chemo in Metastatic NSCLC? (3/4)

EPICS

[redacted]

Can We Improve on Current IO ± Chemo in Metastatic NSCLC? (4/4)

EPICS

[redacted]

APTITUDE HEALTH®

EPICS

Expanding Approaches in Stage IV *EGFR*-Mutated NSCLC

Conference Highlights Presented by
Roy Herbst, MD, PhD

Abstract Selection

EPICS

Abstract	Phase
Abstract LBA77: FLAURA2: Exploratory overall survival (OS) analysis in patients (pts) with poorer prognostic factors treated with osimertinib (osi) ± platinum-pemetrexed chemotherapy (CTx) as first-line (1L) treatment (tx) for *EGFR*-mutated (*EGFR*m) advanced NSCLC (Janne PA, et al)	 Phase III
Abstract LBA72: NorthStar: A Phase II Randomized Study of Osimertinib (OSI) With or Without Local Consolidative Therapy (LCT) for Metastatic *EGFR*-Mutant Non-Small Cell Lung Cancer (NSCLC) (Elamin YY, et al)	 Phase II
Abstract LBA5: Sacituzumab tirumotecan (sac-TMT) vs platinum-based chemotherapy in *EGFR*-mutated (*EGFR*m) non-small cell lung cancer (NSCLC) following progression on EGFR-TKIs: Results from the randomized, multi-center phase 3 OptiTROP-Lung04 study (Zhang L, et al)	 Phase III
Abstract 921MO: Phase 1 Global Study of Iza-Bren (BL-B01D1), an EGFR x HER3 Bispecific Antibody-Drug Conjugate (ADC), in Patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors (Yu HA, et al)	 Phase I
Abstract 1847MO: Activity of Zipalertinib Against Active Central Nervous System (CNS) Metastases in Patients With Non-Small Cell Lung Cancer (NSCLC) Harboring *EGFR* Exon 20 Insertion (Ex20ins)/Other Uncommon Mutations (Yu HA, et al)	 Phase II
Abstract 1848MO: Phase 2 Study of Firmonertinib in Patients With Previously Treated Advanced/Metastatic Non-Small Cell Lung Cancer (mNSCLC) With *EGFR* Exon 20 Insertion (Ex20ins) Mutations (Liu Y, et al)	 Phase II

FLAURA2: Exploratory overall survival (OS) analysis in patients (pts) with poorer prognostic factors treated with osimertinib (osi) ± platinum-pemetrexed chemotherapy (CTx) as first-line (1L) treatment (tx) for *EGFR*-mutated (*EGFR*m) advanced NSCLC

Janne PA, et al. ESMO 2025. Abstract LBA77

EPICS

NorthStar: A Phase II Randomized Study of Osimertinib (OSI) With or Without Local Consolidative Therapy (LCT) for Metastatic *EGFR*-Mutant Non-Small Cell Lung Cancer (NSCLC)

Elamin YY, et al. ESMO 2025. Abstract LBA72

EPICS



NorthStar: A Phase II Randomized Study of Osimertinib (OSI) With or Without Local Consolidative Therapy (LCT) for Metastatic *EGFR*-Mutant Non-Small Cell Lung Cancer (NSCLC)

Elamin YY, et al. ESMO 2025. Abstract LBA72

EPICS





APTITUDE HEALTH®

Sacituzumab tirumotecan (sac-TMT) vs platinum-based chemotherapy in *EGFR*-mutated (*EGFR*m) non-small cell lung cancer (NSCLC) following progression on EGFR-TKIs: Results from the randomized, multi-center phase 3 OptiTROP-Lung04 study

Zhang L, et al. ESMO 2025. Abstract LBA5

EPICS

APTITUDE HEALTH®

Sacituzumab tirumotecan (sac-TMT) vs platinum-based chemotherapy in *EGFR*-mutated (*EGFR*m) non-small cell lung cancer (NSCLC) following progression on EGFR-TKIs: Results from the randomized, multi-center phase 3 OptiTROP-Lung04 study

Zhang L, et al. ESMO 2025. Abstract LBA5

EPICS



Phase 1 Global Study of Iza-Bren (BL-B01D1), an EGFR x HER3 Bispecific Antibody-Drug Conjugate (ADC), in Patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

Yu HA, et al. ESMO 2025. Abstract 921MO

EPICS

APTITUDE HEALTH®

Phase 1 Global Study of Iza-Bren (BL-B01D1), an EGFR x HER3 Bispecific Antibody-Drug Conjugate (ADC), in Patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

Yu HA, et al. ESMO 2025. Abstract 921MO

EPICS



Activity of Zipalertinib Against Active Central Nervous System (CNS) Metastases in Patients With Non-Small Cell Lung Cancer (NSCLC) Harboring *EGFR* Exon 20 Insertion (Ex20ins)/Other Uncommon Mutations

EPICS

Yu HA, et al. ESMO 2025. Abstract 1847MO



Activity of Zipalertinib Against Active Central Nervous System (CNS) Metastases in Patients With Non-Small Cell Lung Cancer (NSCLC) Harboring *EGFR* Exon 20 Insertion (Ex20ins)/Other Uncommon Mutations

Yu HA, et al. ESMO 2025. Abstract 1847MO

EPICS

APTITUDE HEALTH®

Phase 2 Study of Firmonertinib in Patients With Previously Treated Advanced/Metastatic Non-Small Cell Lung Cancer (mNSCLC) With *EGFR* Exon 20 Insertion (Ex20ins)

Liu Y, et al. ESMO 2025. Abstract 1848MO

EPICS

APTITUDE HEALTH®

APTITUDE HEALTH®

EPICS

Expanding Approaches in Stage IV *EGFR*-Mutated NSCLC

Discussion

Expanding Approaches in Stage IV *EGFR*-Mutated NSCLC (1/4)

EPICS

APTITUDE HEALTH®

Expanding Approaches in Stage IV *EGFR*-Mutated NSCLC (2/4)

EPICS

[redacted]

APTITUDE HEALTH®

Expanding Approaches in Stage IV *EGFR*-Mutated NSCLC (3/4)

EPICS

[redacted]

Expanding Approaches in Stage IV *EGFR*-Mutated NSCLC (4/4)

EPICS

[redacted]

APTITUDE HEALTH®

EPICS

Targeted Therapy Beyond *EGFR* in Stage IV NSCLC

Conference Highlights Presented by
Julie Brahmer, MD
Solange Peters, MD, PhD

Abstract Selection (1/2)

EPICS

Abstract	Phase
Abstract 1846MO: Intracranial efficacy of olomorasib, a second-generation KRAS G12C inhibitor, in patients with *KRAS* G12C-mutant NSCLC who have active, untreated brain metastases (Cassier P, et al)	Phase II
Abstract 914O: HRS-7058, a KRAS G12C inhibitor (G12Ci), in advanced solid tumors with *KRAS* G12C mutation: A phase I, multi-center, first-in-human study (Huang D, et al)	Phase I
Abstract 915O: KRAS G12D inhibitor HRS-4642 in patients with *KRAS* G12D-mutant advanced solid tumors: A phase 1 trial (Xiong A, et al)	Phase I
Abstract 916O: Preliminary Phase 1 Results of INCB161734, a Novel Oral *KRAS* G12D Inhibitor, in Patients With Advanced or Metastatic Solid Tumors (Desai J, et al)	Phase I
Abstract 1992P: Targeting *KRAS* codon 13 mutations using combinations with RMC-8839, a novel RAS(ON) G13C-selective, tri-complex inhibitor, in non-small cell lung cancer (Lindsay CR, et al)	**Preclinical study**

Abstract Selection (2/2)

EPICS

Abstract	Phase
Abstract 918O: Telisotuzumab adizutecan (ABBV-400; Temab-A) in patients with *MET*-amplified (MET-amp) advanced solid tumors: Results from a phase 1 study (Murciano-Goroff YR, et al)	
Abstract LBA74: Zongertinib as first-line treatment in patients with advanced *HER2*-mutant NSCLC: Beamion LUNG-1 (Popat S, et al)	
Abstract LBA75: Sevabertinib (BAY 2927088) in advanced *HER2*-mutant non-small cell lung cancer (NSCLC): Results from the SOHO-01 study (Le X, et al)	
Abstract LBA73: Final overall survival (OS) and safety analysis of the phase 3 ALEX study of alectinib vs crizotinib in patients with previously untreated, advanced *ALK*-positive (*ALK*+) non-small cell lung cancer (NSCLC) (Mok TSK, et al)	
Abstract 1987MO: Efficacy of lorlatinib after failure of a first-line ROS1 tyrosine kinase inhibitor (ROS1 TKI) in patients (pts) with advanced *ROS1*-positive non-small cell lung cancer (*ROS1*+ NSCLC) (IFCT-2003 ALBATROS) (Duruisseaux M, et al)	

Intracranial efficacy of olomorasib, a second-generation KRAS G12C inhibitor, in patients with *KRAS* G12C-mutant NSCLC who have active, untreated brain metastases

EPICS

Cassier P, et al. ESMO 2025. Abstract 1846MO

HRS-7058, a KRAS G12C inhibitor (G12Ci), in advanced solid tumors with *KRAS* G12C mutation: A phase I, multi-center, first-in-human study

Huang D, et al. ESMO 2025. Abstract 914O

EPICS

APTITUDE HEALTH®

HRS-7058, a KRAS G12C inhibitor (G12Ci), in advanced solid tumors with *KRAS* G12C mutation: A phase I, multi-center, first-in-human study

Huang D, et al. ESMO 2025. Abstract 914O

EPICS



KRAS G12D inhibitor HRS-4642 in patients with *KRAS* G12D-mutant advanced solid tumors: A phase 1 trial

EPICS

Xiong A, et al. ESMO 2025. Abstract 915O

APTITUDE HEALTH®

Preliminary Phase 1 Results of INCB161734, a Novel Oral KRAS G12D Inhibitor, in Patients With Advanced or Metastatic Solid Tumors

Desai J, et al. ESMO 2025. Abstract 916O

EPICS

APTITUDE HEALTH®

Targeting *KRAS* codon 13 mutations using combinations with RMC-8839, a novel RAS(ON) G13C-selective, tri-complex inhibitor, in non-small cell lung cancer

Lindsay CR, et al. ESMO 2025. Abstract 1992P

EPICS



APTITUDE HEALTH®

Telisotuzumab adizutecan (ABBV-400; Temab-A) in patients with *MET*-amplified (*MET*-amp) advanced solid tumors: Results from a phase 1 study

EPICS

Murciano-Goroff YR, et al. ESMO 2025. Abstract 918O



Telisotuzumab adizutecan (ABBV-400; Temab-A) in patients with *MET*-amplified (*MET*-amp) advanced solid tumors: Results from a phase 1 study

Murciano-Goroff YR, et al. ESMO 2025. Abstract 918O

EPICS



Zongertinib as first-line treatment in patients with advanced *HER2*-mutant NSCLC: Beamion LUNG-1

Popat S, et al. ESMO 2025. Abstract LBA74

EPICS

Sevabertinib (BAY 2927088) in advanced *HER2*-mutant non-small cell lung cancer (NSCLC): Results from the SOHO-01 study

Le X, et al. ESMO 2025. Abstract LBA75

EPICS



Final overall survival (OS) and safety analysis of the phase 3 ALEX study of alectinib vs crizotinib in patients with previously untreated, advanced *ALK*-positive (*ALK*+) non-small cell lung cancer (NSCLC)

Mok TSK, et al. ESMO 2025. Abstract LBA73

EPICS



APTITUDE HEALTH®

Efficacy of lorlatinib after failure of a first-line ROS1 tyrosine kinase inhibitor (ROS1 TKI) in patients (pts) with advanced *ROS1*-positive non-small cell lung cancer (*ROS1*+ NSCLC) (IFCT-2003 ALBATROS)

Duruisseaux M, et al. ESMO 2025. Abstract 1987MO

EPICS



APTITUDE HEALTH®

APTITUDE HEALTH®

EPICS

Targeted Therapy Beyond *EGFR* in Stage IV NSCLC

Discussion

Targeted Therapy Beyond *EGFR* in Stage IV NSCLC (1/4)

EPICS

[redacted]

APTITUDE HEALTH®

Targeted Therapy Beyond *EGFR* in Stage IV NSCLC (2/4)

EPICS

Targeted Therapy Beyond *EGFR* in Stage IV NSCLC (3/4)

EPICS

[redacted]

APTITUDE HEALTH®

Targeted Therapy Beyond *EGFR* in Stage IV NSCLC (4/4)

EPICS

[redacted]

APTITUDE HEALTH®

EPICS

Small Cell Lung Cancer and Mesothelioma

Conference Highlights Presented by
Luis Paz-Ares, MD, PhD
Benjamin Besse, MD, PhD

Abstract Selection (1/2)

EPICS

Abstract	Phase
Abstract 2757O: Tarlatamab with first-line chemoimmunotherapy for extensive stage small cell lung cancer (ES-SCLC): DeLLphi-303 study (Wermke M, et al)	
Abstract 2759MO: DAREON-8: A phase I trial of first-line obrixtamig plus chemotherapy and atezolizumab in extensive-stage small cell lung carcinoma (ES-SCLC) (Peters S, et al)	
Abstract 2762MO: Patterns of disease progression (PD) and efficacy associated with tumour burden from the phase 3 IMforte study of lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in ES-SCLC (Paz-Ares L, et al)	
Abstract 2761O: Chemo-immunotherapy followed by durvalumab and ceralasertib in treatment naïve patients with extensive-stage small cell lung cancer (Furqan M, et al)	

Abstract Selection (2/2)

EPICS

Abstract	Phase
Abstract LBA100: Detailed safety analysis of DeLLphi-304: The first phase 3 study to evaluate tarlatamab versus chemotherapy for previously treated small cell lung cancer (Schuler MH, et al)	Phase III
Abstract LBA101: Tarlatamab as second-line (2L) treatment for small cell lung cancer (SCLC): Outcomes by chemotherapy-free interval (CFI) and prior PD-(L)1 inhibitor use in the phase 3 DeLLphi-304 trial (da Rocha PF, et al)	Phase III
Abstract 2760MO: Intracranial activity of ifinatamab deruxtecan (I-DXd) in patients (pts) with extensive-stage (ES) small cell lung cancer (SCLC) and baseline (BL) brain metastases (BM): Primary analysis of IDeate-Lung01 (da Rocha PF, et al)	Phase II
Abstract 2758MO: Updated results from a phase 1/2 study of gocatamig for small cell lung cancer (SCLC) and other neuroendocrine cancers (Beltran H, et al)	Phase II
Abstract LBA104: Primary results of DREAM3R: DuRvalumab (MEDI4736) with chEmotherapy as first line treAtment in advanced pleural Mesothelioma - A phase 3 Randomised trial (Nowak AK, et al)	Phase III

Tarlatamab with first-line chemoimmunotherapy for extensive stage small cell lung cancer (ES-SCLC): DeLLphi-303 study

Wermke M, et al. ESMO 2025. Abstract 2757O

EPICS

APTITUDE HEALTH®

Tarlatamab with first-line chemoimmunotherapy for extensive stage small cell lung cancer (ES-SCLC): DeLLphi-303 study

Wermke M, et al. ESMO 2025. Abstract 2757O

EPICS

APTITUDE HEALTH®

DAREON-8: A phase I trial of first-line obrixtamig plus chemotherapy and atezolizumab in extensive-stage small cell lung carcinoma

Peters S, et al. ESMO 2025. Abstract 2759MO

EPICS

Patterns of disease progression (PD) and efficacy associated with tumour burden from the phase 3 IMforte study of lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in ES-SCLC

Paz-Ares L, et al. ESMO 2025. Abstract 2762MO

EPICS



APTITUDE HEALTH®

Chemo-immunotherapy followed by durvalumab and ceralasertib in treatment naïve patients with extensive-stage small cell lung cancer

Furqan M, et al. ESMO 2025. Abstract 2761O

EPICS

Detailed safety analysis of DeLLphi-304: The first phase 3 study to evaluate tarlatamab versus chemotherapy for previously treated small cell lung cancer

Schuler MH, et al. ESMO 2025. Abstract LBA100

EPICS

APTITUDE HEALTH®

Tarlatamab as second-line (2L) treatment for small cell lung cancer (SCLC): Outcomes by chemotherapy-free interval (CFI) and prior PD-(L)1 inhibitor use in the phase 3 DeLLphi-304 trial

da Rocha PF, et al. ESMO 2025. Abstract LBA101

EPICS

APTITUDE HEALTH®

Intracranial activity of ifinatamab deruxtecan (I-DXd) in patients (pts) with extensive-stage (ES) small cell lung cancer (SCLC) and baseline (BL) brain metastases (BM): Primary analysis of IDeate-Lung01

da Rocha PF, et al. ESMO 2025. Abstract 2760MO

EPICS

APTITUDE HEALTH®

Updated results from a phase 1/2 study of gocatamig for small cell lung cancer (SCLC) and other neuroendocrine cancers

Beltran H, et al. ESMO 2025. Abstract 2758MO

EPICS



APTITUDE HEALTH®

Primary results of DREAM3R: DuRvalumab (MEDI4736) with chEmotherapy as first line treAtment in advanced pleural Mesothelioma - A phase 3 Randomised trial

EPICS

Nowak AK, et al. ESMO 2025. Abstract LBA104



APTITUDE HEALTH®

APTITUDE HEALTH®

EPICS

Small Cell Lung Cancer and Mesothelioma

Discussion

Small Cell Lung Cancer and Mesothelioma (1/4)

EPICS

Small Cell Lung Cancer and Mesothelioma (2/4)

EPICS

[redacted]

Small Cell Lung Cancer and Mesothelioma (3/4)

EPICS

[redacted]

Small Cell Lung Cancer and Mesothelioma (4/4)

EPICS

[redacted]

APTITUDE HEALTH®

EPICS

Stage I–III NSCLC: Immunotherapy and Targeted Therapy

Conference Highlights Presented by
Heather Wakelee, MD

Abstract Selection

EPICS

Abstract	Phase
Abstract LBA67: Perioperative Pembrolizumab in Early-Stage Non-Small Cell Lung Cancer (NSCLC): 5-Year Follow-Up From KEYNOTE-671 (Wakelee H, et al)	Phase III
Abstract LBA68: CCTG BR.31: Adjuvant durvalumab (D) in resected non-small cell lung cancer (NSCLC): Final overall survival (OS) and minimal residual disease (MRD) analyses (Goss G, et al)	Phase III
Abstract LBA69: SKYSCRAPER-03: Phase 3, open-label, randomised study of atezolizumab (atezo) + tiragolumab (tira) vs durvalumab (durva) in locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC) after platinum-based concurrent chemoradiation (cCRT) (Dziadziuszko R, et al)	Phase III
Abstract LBA65: Neoadjuvant durvalumab (D) + chemotherapy (CT) followed by either surgery (Sx) and adjuvant D or CRT and consolidation D in patients (pts) with resectable or borderline resectable stage IIB–IIIB NSCLC: Interim analysis (IA) of the phase 2 MDT-BRIDGE study (Reck M, et al)	Phase II
Abstract 1787MO: Updated results from the phase III ALINA study of adjuvant alectinib vs chemotherapy (chemo) in patients (pts) with early-stage *ALK*+ non-small cell lung cancer (NSCLC) (Dziadziuszko R, et al)	Phase III
Abstract LBA66: Ensartinib as adjuvant therapy in patients (pts) with stage IB–IIIB *ALK*-positive (*ALK*+) non-small cell lung cancer (NSCLC) after complete tumor resection: The phase III randomized ELEVATE trial (Yue D, et al)	Phase III
Abstract 1817MO: Molecular residual disease (MRD) analysis from the LAURA study of osimertinib (osi) in unresectable (UR) stage III *EGFR*-mutated (*EGFR*m) NSCLC (Arriola Aperribay E, et al)	Phase III

Perioperative Pembrolizumab in Early-Stage Non-Small Cell Lung Cancer (NSCLC): 5-Year Follow-Up From KEYNOTE-671

Wakelee H, et al. ESMO 2025. Abstract LBA67

EPICS

APTITUDE HEALTH®

CCTG BR.31: Adjuvant durvalumab (D) in resected non-small cell lung cancer (NSCLC): Final overall survival (OS) and minimal residual disease (MRD) analyses

EPICS

Goss G, et al. ESMO 2025. Abstract LBA68

APTITUDE HEALTH®

SKYSCRAPER-03: Phase 3, open-label, randomised study of atezolizumab (atezo) + tiragolumab (tira) vs durvalumab (durva) in locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC) after platinum-based concurrent chemoradiation (cCRT)

EPICS

Dziadziuszko R, et al. ESMO 2025. Abstract LBA69

APTITUDE HEALTH®

Neoadjuvant durvalumab (D) + chemotherapy (CT) followed by either surgery (Sx) and adjuvant D or CRT and consolidation D in patients (pts) with resectable or borderline resectable stage IIB–IIIB NSCLC: Interim analysis (IA) of the phase 2 MDT-BRIDGE study

Reck M, et al. ESMO 2025. Abstract LBA65

EPICS



APTITUDE HEALTH®

Updated results from the phase III ALINA study of adjuvant alectinib vs chemotherapy (chemo) in patients (pts) with early-stage *ALK*+ non-small cell lung cancer (NSCLC)

Dziadziuszko R, et al. ESMO 2025. Abstract 1787MO

EPICS

Ensartinib as adjuvant therapy in patients (pts) with stage IB–IIIB *ALK*-positive (*ALK*+) non-small cell lung cancer (NSCLC) after complete tumor resection: The phase III randomized ELEVATE trial

EPICS

Yue D, et al. ESMO 2025. Abstract LBA66

Ensartinib as adjuvant therapy in patients (pts) with stage IB–IIIB *ALK*-positive (*ALK*+) non-small cell lung cancer (NSCLC) after complete tumor resection: The phase III randomized ELEVATE trial

EPICS

Yue D, et al. ESMO 2025. Abstract LBA66



Molecular residual disease (MRD) analysis from the LAURA study of osimertinib (osi) in unresectable (UR) stage III *EGFR*-mutated (*EGFR*m) NSCLC

Arriola Aperribay E, et al. ESMO 2025. Abstract 1817MO

EPICS

APTITUDE HEALTH®

APTITUDE HEALTH®

EPICS

Stage I–III NSCLC: Immunotherapy and Targeted Therapy

Discussion

Stage I–III NSCLC: Immunotherapy and Targeted Therapy (1/4)

EPICS

APTITUDE HEALTH®

Stage I–III NSCLC: Immunotherapy and Targeted Therapy (2/4)

EPICS

[redacted]

Stage I–III NSCLC: Immunotherapy and Targeted Therapy (3/4)

EPICS

[redacted]

Stage I–III NSCLC: Immunotherapy and Targeted Therapy (4/4)

EPICS

[redacted]

APTITUDE HEALTH®

US 5901-B Peachtree Dunwoody Road
Suite 415, Atlanta, GA 30328, US

EU Laan van Nieuw Oost-Indië 133 F
2593 BM The Hague, the Netherlands

UK 6th Floor, 2 Kingdom Street
London, W2 6BD, United Kingdom

aptitudehealth.com